Abstract
The role of inflammation in the development and progression of cardiovascular diseases is well established. Systemic inflammation and immune system play a central role in atherogenesis. The strong dependence of the atherosclerotic process on both a state of continuous low grade inflammation and the presence of lipid abnormalities gave impetus to research the association between hyperlipidemia and inflammatory status. In experimental and clinical studies, several inflammatory markers such as C-reactive protein, tumor necrosis factor-alpha, interleukin 6, nuclear factor kappa-β, adhesion molecules, serum amyloid-α, lipoprotein-associated phospholipase A2, fibrinogen and sCD40 ligand are associated with lipids level. Although, cholesterol lowering treatment has several important beneficial effects, there is still little clinical experience or data from clinical trials, in order to treat patients with hyperlipidemia and impaired inflammatory status.
Keywords: Hyperlipidemia, inflammatory markers, cholesterol, lipids, triglycerides, inflammation, atherogenesis, C-Reactive Protein (CRP), TNF-α, nicotinic acid
Current Pharmaceutical Design
Title: Inflammatory Markers in Hyperlipidemia: From Experimental Models to Clinical Practice
Volume: 17 Issue: 37
Author(s): Gerasimos Siasos, Dimitris Tousoulis, Evangelos Oikonomou, Marina Zaromitidou, Christodoulos Stefanadis and Athanasios G. Papavassiliou
Affiliation:
Keywords: Hyperlipidemia, inflammatory markers, cholesterol, lipids, triglycerides, inflammation, atherogenesis, C-Reactive Protein (CRP), TNF-α, nicotinic acid
Abstract: The role of inflammation in the development and progression of cardiovascular diseases is well established. Systemic inflammation and immune system play a central role in atherogenesis. The strong dependence of the atherosclerotic process on both a state of continuous low grade inflammation and the presence of lipid abnormalities gave impetus to research the association between hyperlipidemia and inflammatory status. In experimental and clinical studies, several inflammatory markers such as C-reactive protein, tumor necrosis factor-alpha, interleukin 6, nuclear factor kappa-β, adhesion molecules, serum amyloid-α, lipoprotein-associated phospholipase A2, fibrinogen and sCD40 ligand are associated with lipids level. Although, cholesterol lowering treatment has several important beneficial effects, there is still little clinical experience or data from clinical trials, in order to treat patients with hyperlipidemia and impaired inflammatory status.
Export Options
About this article
Cite this article as:
Siasos Gerasimos, Tousoulis Dimitris, Oikonomou Evangelos, Zaromitidou Marina, Stefanadis Christodoulos and G. Papavassiliou Athanasios, Inflammatory Markers in Hyperlipidemia: From Experimental Models to Clinical Practice, Current Pharmaceutical Design 2011; 17 (37) . https://dx.doi.org/10.2174/138161211798764780
DOI https://dx.doi.org/10.2174/138161211798764780 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Noninvasive Assessment of Cytokines in Occupational Respiratory Diseases
Recent Patents on Inflammation & Allergy Drug Discovery A Comprehensive Review on Recent advances in Synthesis & Pharmacotherapeutic potential of Benzothiazoles
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry The Manzamines as an Example of the Unique Structural Classes Available for the Discovery and Optimization of Infectious Disease Controls Based on Marine Natural Products
Current Pharmaceutical Design The Vicious Circle of Leptin and Obesity
Current Nutrition & Food Science Second-Generation Antipsychotic Agents: A Review of Safety Profiles
Current Psychiatry Reviews Predicting Drug Metabolism Induction In Silico
Current Topics in Medicinal Chemistry Chalcones as Versatile Synthons for the Synthesis of 5- and 6-membered Nitrogen Heterocycles
Current Organic Chemistry Postprandial Hypertriglyceridaemia Revisited in the Era of Non-Fasting Lipid Profile Testing: A 2019 Expert Panel Statement, Main Text
Current Vascular Pharmacology Angiogenesis and the Heart
Recent Patents on Cardiovascular Drug Discovery Novel Lipid and Polymeric Materials as Delivery Systems for Nucleic Acid Based Drugs
Current Drug Metabolism Strain and Strain Rate Imaging by Echocardiography - Basic Concepts and Clinical Applicability
Current Cardiology Reviews Editorial [Hot Topic:Advances in Alzheimer Therapy: Understanding Pharmacological Approaches to the Disease (Guest Editors: Ana Martinez, Debomoy K. Lahiri, Ezio Giacobini and Nigel H. Greig)]
Current Alzheimer Research The Management of Dyslipidaemia in Patients with Type 2 Diabetes Mellitus Receiving Lipid-Lowering Drugs: A Sub-Analysis of the CEPHEUS Findings
Current Vascular Pharmacology Enzymes To Die For: Exploiting Nucleotide Metabolizing Enzymes for Cancer Gene Therapy
Current Gene Therapy Use of Biguanides and the Risk of Colorectal Cancer: A Register-Based Cohort Study
Current Drug Safety Morbidity and Mortality Associated with Pharmacotherapy. Evolution and Current Concept of Drug-Related Problems
Current Pharmaceutical Design Current Evidence for Antithrombotic Therapy after Peripheral Vascular Interventions
Current Vascular Pharmacology Neutrophil Gelatinase-Associated Lipocalin (NGAL) as a New Biomarker for Non – Acute Kidney Injury (AKI) Diseases
Inflammation & Allergy - Drug Targets (Discontinued) Orekhov`s Method: Reassessment of In vitro Lipid Uptake Assays
Recent Advances in Cardiovascular Drug Discovery (Discontinued) Subclinical Thyroid Dysfunction and the Risk of Cardiovascular Disease
Current Pharmaceutical Design